| Ytd | -58.34% | |
| 1y | 127.88% |
| Open | 11.17 | Prev Close | 11.94 | Low | 9.74 | High | 11.17 | Mkt Cap | 910.16M |
| Vol | 1.60M | Avg Vol | 1.44M | EPS | -2.02 | P/E | -5.16 | Forward P/E | -4.86 |
| Beta | 2.03 | Short Ratio | 7.94 | Inst. Own | 118.48% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-10 | 50-d Avg | 11.32 | 200-d Avg | 17.52 | 1yr Est | 40.70 |
OLMA News
U.S. stock futures mostly lower. OppFi (OPFI) shares fall after missing Q2 earnings and cutting FY26
Gainers P3 Health Partners (NASDAQ:PIII) shares increased by 24.1% to $15.92 during Monday's af
Olema Pharmaceuticals (NASDAQ:OLMA) reported quarterly losses of $(0.61) per share which missed the
SAN FRANCISCO, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Onco
Gainers Gossamer Bio (NASDAQ:GOSS) shares rose 28.8% to $0.26 during Monday's after-market sess
Olema Pharmaceuticals, Inc. (OLMA) Presents at Goldman Sachs 47th Annual Global Healthcare Conferenc
SAN FRANCISCO, June 02, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Onco
Study to evaluate OP-3136, Olema's novel KAT6 inhibitor, in combination with darolutamide in approxi
OP-3136 monotherapy was well-tolerated with no dose-limiting toxicities observed and no discontinuat
SAN FRANCISCO, May 19, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncol
SAN FRANCISCO, May 04, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncol
SAN FRANCISCO, April 29, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Onc
SAN FRANCISCO, April 21, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Onc
Olema Pharmaceuticals (NASDAQ: OLMA - Get Free Report) and Ligand Pharmaceuticals (NASDAQ: LGND - Ge
SG Americas Securities LLC bought a new stake in shares of Olema Pharmaceuticals, Inc. (NASDAQ: OLMA
SAN FRANCISCO, April 02, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Onc
Paradigm Biocapital Advisor increased its stake in Olema Pharmaceuticals by 750,000 shares in Q4 202
Olema Pharmaceuticals (OLMA) is technically in oversold territory now, so the heavy selling pressure
Top analysts changed outlook on top names. Mizuho, Needham, Rothschild & Co, HC Wainwright &
Cormorant Asset Management established a new stake in Olema Pharmaceuticals, purchasing 2,750,000 sh
On-track to report top-line data in the fall of 2026 from the pivotal Phase 3 OPERA-01 trial of pala
LOS ANGELES--(BUSINESS WIRE)--Olema Pharmaceuticals, Inc. Investigated on Behalf of Investors - Cont
Olema Pharmaceuticals Inc. (NASDAQ: OLMA) stock is trading lower on Monday, in reaction to data from
U.S. stock futures lower, with Dow futures down over 1%. BETA Technologies (NYSE: BETA) fell in pre-
Lisata Therapeutics (LSTA) surged 20.3% to $5.03 in pre-market trading after agreeing to be taken pr
SAN FRANCISCO, March 03, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Onc
Olema Pharmaceuticals, Inc. (OLMA) Presents at Citi's 2026 Virtual Oncology Leadership Summit Transc
On Friday, 1043 companies hit new 52-week lows.
During Thursday, 849 stocks hit new 52-week lows.
Wednesday's session saw 784 companies set new 52-week lows.
On Friday, 431 companies hit new 52-week lows.
Upgrades
During Tuesday's trading, 505 companies set new 52-week lows.
On Friday, 313 companies hit new 52-week lows.
During Monday's session, 291 companies made new 52-week lows. Also check out this: Insid
During Friday's session, 445 companies made new 52-week lows.